HBM Global Biotechnology Fund P USD Cap

Reference Data

ISIN LU1540962054
Valor Number 35004489
Bloomberg Global ID
Fund Name HBM Global Biotechnology Fund P USD Cap
Fund Provider HBM Partners AG Zug, Schweiz
Phone: +41 43 888 71 71
E-Mail: investorrelations@hbmpartners.com
Web: www.hbmpartners.com
Fund Provider HBM Partners AG
Representative in Switzerland FundPartner Solutions (Suisse) SA
Genève 75
Distributor(s) FundPartner Solutions (Suisse) S.A.
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition Combination of issuing commission charged by the fund management company and transaction fee charged by the fund
Redemption Condition Combination of redemption commission charged by the fund management company and transaction fee charged by the fund
Investment Strategy *** The investment objective of the Sub-Fund is to achieve long-term capital growth. The goal is to generate a value trend that exceeds the performance of the NASDAQ Biotechnology Index (the “Benchmark”). No guarantee can be given that the investment objective will be achieved.
Peculiarities

Fund Prices

Current Price * 464.73 USD 20.12.2024
Previous Price * 461.78 USD 19.12.2024
52 Week High * 522.40 USD 08.11.2024
52 Week Low * 426.07 USD 19.04.2024
NAV * 464.73 USD 20.12.2024
Issue Price * 464.73 USD 20.12.2024
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 20,919,884
Unit/Share Assets *** 16,778,983
Trading Information SIX

Performance

YTD Performance +1.34% 29.12.2023
20.12.2024
YTD Performance (in CHF) +7.62% 29.12.2023
20.12.2024
1 month -1.66% 20.11.2024
20.12.2024
3 months -9.59% 20.09.2024
20.12.2024
6 months +1.09% 20.06.2024
20.12.2024
1 year +11.08% 20.12.2023
20.12.2024
2 years +12.58% 21.12.2022
20.12.2024
3 years +0.20% 22.12.2021
20.12.2024
5 years +17.23% 27.12.2019
20.12.2024

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

argenx SE 6.12%
Amgen Inc 6.08%
Gilead Sciences Inc 4.75%
Zealand Pharma AS 4.58%
Vertex Pharmaceuticals Inc 4.39%
Regeneron Pharmaceuticals Inc 3.97%
Biohaven Ltd 3.77%
Alnylam Pharmaceuticals Inc 3.63%
UCB SA 3.40%
AstraZeneca PLC ADR 2.94%
Last data update 30.09.2024

Cost / Risk

TER 0.0133%
TER date 31.01.2018
Performance Fee *** 15.00%
PTR
Max. Management Fee *** 1.10%
Ongoing Charges *** 1.64%
SRRI ***
SRRI date *** 30.11.2024

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 ***

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)